Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia.
ERJ Open Res
; 10(2)2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38444654
ABSTRACT
Background:
In interstitial pneumonia (IP)-associated lung cancer, immune checkpoint inhibitor pneumonitis (ICIP) is common with immune checkpoint inhibitor (ICI) treatment. The purpose of the present study was to clarify the safety and efficacy of ICI treatment for patients with lung cancer with IP.Methods:
This multicentre retrospective observational study was conducted from June 2016 to December 2020 in patients with primary lung cancer with IP who received ICI treatment.Results:
A total of 200 patients (median age 70â years; male/female, 176/24) were enrolled from 27 institutions. ICIP occurred in 61 patients (30.5%), pneumonitis grades 3-5 in 32 patients (15.5%) and death in nine patients (4.5%). The common computed tomography pattern of ICIP was organising pneumonia in 29 patients (47.5%). Subsequently, diffuse alveolar damage (DAD) pattern was observed in 19 patients (31.1%) who had a significantly worse prognosis than those with a non-DAD pattern (median progression-free survival (PFS) 115â days versus 226â days, p=0.042; median overall survival (OS) 334â days versus 1316â days, p<0.001). Immune-related adverse events (irAEs) occurred in approximately 50% of patients. Patients with irAEs (n=100) had a better prognosis than those without irAEs (n=100) (median PFS 200â days versus 77â days, p<0.001; median OS 597â days versus 390â days p=0.0074). The objective response rate and disease control rate were 41.3% and 68.5%, respectively.Conclusions:
Although ICI treatment was effective for patients with lung cancer with IP, ICIP developed in approximately 30% of patients. Patients with irAEs had a significantly better PFS and OS than those without irAEs.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
4_TD
/
6_ODS3_enfermedades_notrasmisibles
Problema de saúde:
4_pneumonia
/
6_trachea_bronchus_lung_cancer
Idioma:
En
Revista:
ERJ Open Res
/
ERJ open res
/
ERJ open research
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Japão